Vaccine Microarray Patches (VMAPs) Market Report – Research, Industry Analysis Reports and Market Demands

Global Vaccine Microarray Patches (VMAPs) Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global Vaccine Microarray Patches (VMAPs) Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Dissolving
- 1.3.3 Non-dissolving
1.4 Market Analysis by Microneedle Material
- 1.4.1 Overview: Global Vaccine Microarray Patches (VMAPs) Consumption Value by Microneedle Material: 2021 Versus 2025 Versus 2032
- 1.4.2 Hyaluronic Acid
- 1.4.3 Taurine
- 1.4.4 Triple-helical Collagen
1.5 Market Analysis by Form of Use
- 1.5.1 Overview: Global Vaccine Microarray Patches (VMAPs) Consumption Value by Form of Use: 2021 Versus 2025 Versus 2032
- 1.5.2 Patches
- 1.5.3 Direct Topical
1.6 Market Analysis by Application
- 1.6.1 Overview: Global Vaccine Microarray Patches (VMAPs) Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.6.2 Routine Childhood Immunization
- 1.6.3 Adolescent / Pre-adolescent Prevention
- 1.6.4 Travel / Endemic Exposure / Post-exposure
- 1.6.5 Respiratory Vaccines with Recurring Demand
- 1.6.6 Outbreak / Pandemic Preparedness
1.7 Global Vaccine Microarray Patches (VMAPs) Market Size & Forecast
- 1.7.1 Global Vaccine Microarray Patches (VMAPs) Consumption Value (2021 & 2025 & 2032)
- 1.7.2 Global Vaccine Microarray Patches (VMAPs) Sales Quantity (2021-2032)
- 1.7.3 Global Vaccine Microarray Patches (VMAPs) Average Price (2021-2032)

2 Manufacturers Profiles

3 Competitive Environment: Vaccine Microarray Patches (VMAPs) by Manufacturer

3.1 Global Vaccine Microarray Patches (VMAPs) Sales Quantity by Manufacturer (2021-2026)
3.2 Global Vaccine Microarray Patches (VMAPs) Revenue by Manufacturer (2021-2026)
3.3 Global Vaccine Microarray Patches (VMAPs) Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Vaccine Microarray Patches (VMAPs) by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Vaccine Microarray Patches (VMAPs) Manufacturer Market Share in 2025
- 3.4.3 Top 6 Vaccine Microarray Patches (VMAPs) Manufacturer Market Share in 2025
3.5 Vaccine Microarray Patches (VMAPs) Market: Overall Company Footprint Analysis
- 3.5.1 Vaccine Microarray Patches (VMAPs) Market: Region Footprint
- 3.5.2 Vaccine Microarray Patches (VMAPs) Market: Company Product Type Footprint
- 3.5.3 Vaccine Microarray Patches (VMAPs) Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Vaccine Microarray Patches (VMAPs) Market Size by Region
- 4.1.1 Global Vaccine Microarray Patches (VMAPs) Sales Quantity by Region (2021-2032)
- 4.1.2 Global Vaccine Microarray Patches (VMAPs) Consumption Value by Region (2021-2032)
- 4.1.3 Global Vaccine Microarray Patches (VMAPs) Average Price by Region (2021-2032)
4.2 North America Vaccine Microarray Patches (VMAPs) Consumption Value (2021-2032)
4.3 Europe Vaccine Microarray Patches (VMAPs) Consumption Value (2021-2032)
4.4 Asia-Pacific Vaccine Microarray Patches (VMAPs) Consumption Value (2021-2032)
4.5 South America Vaccine Microarray Patches (VMAPs) Consumption Value (2021-2032)
4.6 Middle East & Africa Vaccine Microarray Patches (VMAPs) Consumption Value (2021-2032)

5 Market Segment by Type

5.1 Global Vaccine Microarray Patches (VMAPs) Sales Quantity by Type (2021-2032)
5.2 Global Vaccine Microarray Patches (VMAPs) Consumption Value by Type (2021-2032)
5.3 Global Vaccine Microarray Patches (VMAPs) Average Price by Type (2021-2032)

6 Market Segment by Application

6.1 Global Vaccine Microarray Patches (VMAPs) Sales Quantity by Application (2021-2032)
6.2 Global Vaccine Microarray Patches (VMAPs) Consumption Value by Application (2021-2032)
6.3 Global Vaccine Microarray Patches (VMAPs) Average Price by Application (2021-2032)

7 North America

7.1 North America Vaccine Microarray Patches (VMAPs) Sales Quantity by Type (2021-2032)
7.2 North America Vaccine Microarray Patches (VMAPs) Sales Quantity by Application (2021-2032)
7.3 North America Vaccine Microarray Patches (VMAPs) Market Size by Country
- 7.3.1 North America Vaccine Microarray Patches (VMAPs) Sales Quantity by Country (2021-2032)
- 7.3.2 North America Vaccine Microarray Patches (VMAPs) Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

8.1 Europe Vaccine Microarray Patches (VMAPs) Sales Quantity by Type (2021-2032)
8.2 Europe Vaccine Microarray Patches (VMAPs) Sales Quantity by Application (2021-2032)
8.3 Europe Vaccine Microarray Patches (VMAPs) Market Size by Country
- 8.3.1 Europe Vaccine Microarray Patches (VMAPs) Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Vaccine Microarray Patches (VMAPs) Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

9.1 Asia-Pacific Vaccine Microarray Patches (VMAPs) Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Vaccine Microarray Patches (VMAPs) Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Vaccine Microarray Patches (VMAPs) Market Size by Region
- 9.3.1 Asia-Pacific Vaccine Microarray Patches (VMAPs) Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Vaccine Microarray Patches (VMAPs) Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

10.1 South America Vaccine Microarray Patches (VMAPs) Sales Quantity by Type (2021-2032)
10.2 South America Vaccine Microarray Patches (VMAPs) Sales Quantity by Application (2021-2032)
10.3 South America Vaccine Microarray Patches (VMAPs) Market Size by Country
- 10.3.1 South America Vaccine Microarray Patches (VMAPs) Sales Quantity by Country (2021-2032)
- 10.3.2 South America Vaccine Microarray Patches (VMAPs) Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

11.1 Middle East & Africa Vaccine Microarray Patches (VMAPs) Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Vaccine Microarray Patches (VMAPs) Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Vaccine Microarray Patches (VMAPs) Market Size by Country
- 11.3.1 Middle East & Africa Vaccine Microarray Patches (VMAPs) Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Vaccine Microarray Patches (VMAPs) Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

12.1 Vaccine Microarray Patches (VMAPs) Market Drivers
12.2 Vaccine Microarray Patches (VMAPs) Market Restraints
12.3 Vaccine Microarray Patches (VMAPs) Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of Vaccine Microarray Patches (VMAPs) and Key Manufacturers
13.2 Manufacturing Costs Percentage of Vaccine Microarray Patches (VMAPs)
13.3 Vaccine Microarray Patches (VMAPs) Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 Vaccine Microarray Patches (VMAPs) Typical Distributors
14.3 Vaccine Microarray Patches (VMAPs) Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Vaccine Microarray Patches (VMAPs) market size was valued at US$ 37.87 million in 2025 and is forecast to a readjusted size of US$ 234 million by 2032 with a CAGR of 30.1% during review period.
In 2025, global sales of Vaccine Microarray Patches (VMAPs) reached approximately 16 million pcs, with an average market price of about USD 2.30 pc, an annual production capacity of roughly 2.15 million pcs, and an industry-average gross margin of approximately 40%.
Vaccine Microarray Patches (VMAPs) are integrated vaccine dosage forms and delivery systems comprising arrays of microscopic projections, needles or cone-shaped structures mounted on a patch substrate and designed to place vaccine antigens, adjuvants, nucleic-acid constructs or other immunologically active components into the epidermal or superficial dermal layers of the skin. Vaccine loading may be achieved through dry coating, incorporation into dissolvable or biodegradable polymers, detachable tips, reservoir-assisted delivery or other precision formulation and deposition techniques. A complete VMAP product may include the microarray, vaccine formulation, adhesive or backing layer, protective packaging and a manual or spring-assisted single-use applicator. Its critical manufacturing and performance attributes include projection geometry, mechanical strength, vaccine loading uniformity, insertion reliability, dissolution or release time, antigen stability, sterility, residual dose, application feedback and compatibility with scalable production. VMAPs are intended to provide rapid and reproducible cutaneous vaccination while reducing dependence on conventional needles and syringes, sharps disposal and highly trained vaccinators. Their principal prospective uses include routine childhood immunisation, supplementary immunisation campaigns, seasonal adult vaccination, outbreak response, pandemic preparedness and delivery in settings where cold-chain capacity, healthcare personnel or access to fixed vaccination sites is constrained.
Vaccine Microarray Patches (VMAPs) should be viewed as integrated vaccine–device combination products rather than as a simple extension of conventional transdermal patches or cosmetic microneedles. The relevant industry boundary includes vaccine-loaded arrays, formulation and loading processes, application devices, clinical or pilot manufacturing and directly associated contract development and manufacturing services. It does not extend to ordinary intradermal syringes, needle-free jet injectors, unmedicated microneedle devices or vaccine antigen suppliers that have no responsibility for the patch itself. The most advanced public-health use case remains measles–rubella vaccination. WHO pipeline assessments identify Micron Biomedical and Vaxxas as the two principal MR-MAP developers with human clinical programmes, while QuadMedicine has advanced a hepatitis B microneedle vaccine into human investigation and a broader group of companies is working on influenza, rotavirus, COVID-19, nucleic-acid and multivalent vaccine candidates. Consequently, the 2025 and 2026 market cannot be interpreted as a conventional commercial vaccine market measured by approved doses sold. Current economic activity is largely composed of sponsored development programmes, clinical-patch supply, formulation work, technology licensing, engineering batches and manufacturing scale-up. Under a strict approved-product sales definition, the market remains effectively pre-commercial; under the adopted industry-economic-activity definition, it is measurable but still small and highly dependent on project timing.
Demand is likely to emerge first where the operational burden of needle-and-syringe vaccination is greatest. Measles–rubella campaigns, hepatitis B birth-dose delivery, seasonal influenza, outbreak response and immunisation in remote or resource-constrained settings offer clearer early value propositions than immediate replacement of all routine injections. The commercial case will depend on more than immunogenicity. Procurers and regulators will evaluate total delivered cost, residual vaccine dose, application success, thermostability, packaging density, waste handling, user training and the ability to manufacture hundreds of millions of consistent units. From a technology perspective, solid-coated high-density arrays can provide very rapid delivery but require precise coating and reproducible application forces; dissolving patches eliminate residual sharps but face formulation, moisture and payload constraints; detachable-tip and programmed-release designs may enable prime–boost delivery from a single application but add manufacturing and regulatory complexity. The market’s medium-term growth therefore depends on regulatory de-risking and manufacturing performance rather than on scientific novelty alone. Gavi planning assumptions place initial MR-MAP licensure and WHO prequalification around 2030, making the second half of the forecast period the likely point at which commercial procurement could begin to contribute meaningfully. Before that transition, investment will remain concentrated in clinical validation, dedicated facilities, quality systems, applicator design and partnerships between vaccine owners and MAP manufacturers.
This report is a detailed and comprehensive analysis for global Vaccine Microarray Patches (VMAPs) market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Vaccine Microarray Patches (VMAPs) market size and forecasts, in consumption value ($ Million), sales quantity (K Pcs), and average selling prices (US$/Pc), 2021-2032
Global Vaccine Microarray Patches (VMAPs) market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Pcs), and average selling prices (US$/Pc), 2021-2032
Global Vaccine Microarray Patches (VMAPs) market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Pcs), and average selling prices (US$/Pc), 2021-2032
Global Vaccine Microarray Patches (VMAPs) market shares of main players, shipments in revenue ($ Million), sales quantity (K Pcs), and ASP (US$/Pc), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Vaccine Microarray Patches (VMAPs)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Vaccine Microarray Patches (VMAPs) market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Vaxxas Pty Ltd, Micron Biomedical, Inc., QuadMedicine, Inc., Inventprise, LLC, Kindeva Drug Delivery, LTS Lohmann Therapie-Systeme AG, RAPHAS Co., Ltd., WCC BIOMEDICAL CO., LTD., Gylden Pharma Limited, Shenzhen BioQingLam Biotechnology Co., Ltd., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Vaccine Microarray Patches (VMAPs) market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Dissolving
Non-dissolving
Market segment by Microneedle Material
Hyaluronic Acid
Taurine
Triple-helical Collagen
Market segment by Form of Use
Patches
Direct Topical
Market segment by Application
Routine Childhood Immunization
Adolescent / Pre-adolescent Prevention
Travel / Endemic Exposure / Post-exposure
Respiratory Vaccines with Recurring Demand
Outbreak / Pandemic Preparedness
Major players covered
Vaxxas Pty Ltd
Micron Biomedical, Inc.
QuadMedicine, Inc.
Inventprise, LLC
Kindeva Drug Delivery
LTS Lohmann Therapie-Systeme AG
RAPHAS Co., Ltd.
WCC BIOMEDICAL CO., LTD.
Gylden Pharma Limited
Shenzhen BioQingLam Biotechnology Co., Ltd.
CeraVx B.V.
Verndari, Inc.
MEDRx Co., Ltd.
Advaccine Biopharmaceuticals Suzhou Co., Ltd.
Youwe (Zhuhai) Biotechnology Co., Ltd.
CosMED Pharmaceutical Co., Ltd.
SingleTimeMicroneedles, Inc.
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Vaccine Microarray Patches (VMAPs) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Vaccine Microarray Patches (VMAPs), with price, sales quantity, revenue, and global market share of Vaccine Microarray Patches (VMAPs) from 2021 to 2026.
Chapter 3, the Vaccine Microarray Patches (VMAPs) competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Vaccine Microarray Patches (VMAPs) breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Vaccine Microarray Patches (VMAPs) market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Vaccine Microarray Patches (VMAPs).
Chapter 14 and 15, to describe Vaccine Microarray Patches (VMAPs) sales channel, distributors, customers, research findings and conclusion.

Buy now